Drug utilisation pattern over 3 years in the real‐world treatment of type II diabetes

Abstract

Introduction Non‐adherence to therapy is very common in patients with type II diabetes, leading to an increase in morbidity and mortality. The development of new oral therapies following metformin has increased the possibilities of treatment but little has been done in terms of improving medication adherence. The goal of the following study is to evaluate adherence and persistence over a period of 3 years in real‐world diabetic patients and describe the comorbidities found in the group of patients studied. Material and Methodology A non‐interventional pharmacological observational study was conducted by examining all therapies from 2011 to 2019 at a local health centre in Pescara (ASL). The medication adherence and persistence over a 3‐year period were calculated using the pharmacy‐refill method. The identification of the comorbidities was carried out in accordance with the Anatomical Therapeutic Chemical (ATC) Classification system at the fourth level. Results A total of 19 600 patients undergoing treatment for type II diabetes from January 2011 to December 2019 were analysed. The absolute adherence value at 3 years was 0.68 ± 0.23. The 3‐year persistence curves showed a statistically significant difference (P < .0001). The ATCs with highest figures in the entire study group were: A02BC, B01AC and C10AA with 14 220, 13 934 and 10 858 patients, respectively. Conclusions Adherence to therapy was suboptimal, while persistence curves showed a statistically significant difference, with patients treated with metformin showing better results. Comorbidities analysed showed a greater relevance of heart disease.

Distinct associations of self‐monitoring of blood glucose with glycemic control and hypoglycemia between groups of recently diagnosed and long‐term follow‐up type 2 diabetes: The Taiwan Diabetes Registry

“…We suppose that decline in SMBG adherence over time might be one reason, while the possibility of reverse causality cannot be excluded. Our results, in conjunction with previous findings, 28‐30,32‐38 highlight the importance of maintaining SMBG adherence in patients with prolonged diabetes duration.…”

“…We suppose that decline in SMBG adherence over time might be one reason, while the possibility of reverse causality cannot be excluded. Our results, in conjunction with previous findings, [28][29][30][32][33][34][35][36][37][38] highlight the importance of maintaining SMBG adherence in patients with prolonged diabetes duration. Interestingly, we observed that SMBG was independently associated with hypoglycemia in both study populations.…”

Effect and safety of combined Gegen Qinlian decoction/metformin in the treatment of diabetes mellitus in patients, and its influence on serum C peptide and glycosylated hemoglobin

“…Patients with diabetes mellitus (DM) present with abnormal blood glucose and long-term organ damage, leading to cardiovascular diseases and increasing the disease-associated burden [1][2][3]. Therefore, early diagnosis and treatment should be carried out to strictly control the occurrence of DM.…”

Adherence to newer second‐line oral antidiabetic drugs among people with type 2 diabetes—A systematic review

“…The second‐line OADs investigated in these studies were the DPP4i alogliptin and the SGLT2is canagliflozin, dapagliflozin, and empagliflozin. Furthermore, Gordon et al., 21 Romagnoli et al., 22 and Strain et al. 23 investigated adherence to SGLT2is, but did not report the type of SGLT2is being investigated.…”